These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [An open, noncomparative multicenter study of the efficacy and safety of itraconazole injections and high dose capsules in chronic pulmonary aspergillosis]. Tomioka H, Kaneda T, Kida Y, Kaneko M, Fujii H, Hayashi M, Tomii K, Tada K, Suzuki Y, Karino T. Kansenshogaku Zasshi; 2011 Nov; 85(6):644-51. PubMed ID: 22250455 [Abstract] [Full Text] [Related]
3. Effective plasma concentrations of itraconazole and its active metabolite for the treatment of pulmonary aspergillosis. Nakamura Y, Matsumoto K, Sato A, Morita K. J Infect Chemother; 2020 Feb; 26(2):170-174. PubMed ID: 31481305 [Abstract] [Full Text] [Related]
6. Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in multicenter study. Yoshida K, Kurashima A, Kamei K, Oritsu M, Ando T, Yamamoto T, Niki Y. J Infect Chemother; 2012 Jun; 18(3):378-85. PubMed ID: 22526387 [Abstract] [Full Text] [Related]
8. [A case of pulmonary aspergilloma successfully treated with transbronchial intracavitary itraconazole]. Tani S, Tomioka H, Tsuchimoto K, Kaneda T, Kubota M, Kaneko M, Fujii H. Nihon Kokyuki Gakkai Zasshi; 2008 Dec; 46(12):997-1002. PubMed ID: 19195200 [Abstract] [Full Text] [Related]
9. Pharmacokinetic investigation of oral itraconazole in stratum corneum level of tinea pedis. Morimoto K, Tanuma H, Kikuchi I, Kusunoki T, Kawana S. Mycoses; 2004 Apr; 47(3-4):104-14. PubMed ID: 15078426 [Abstract] [Full Text] [Related]
10. [Correlations between drug plasma concentration and adverse effects in patients treated with itraconazole for pulmonary aspergilloma]. Maesaki S, Hashiguchi K, Tomiyama Y, Sasaki E, Miyazaki H, Miyazaki Y, Higashiyama Y, Tomono K, Tashiro T, Kohno S. Nihon Kokyuki Gakkai Zasshi; 1999 Nov; 37(11):875-9. PubMed ID: 18217308 [Abstract] [Full Text] [Related]
11. Selection of Oral Antifungals for Initial Maintenance Therapy in Chronic Pulmonary Aspergillosis: A Longitudinal Analysis. Tashiro M, Takazono T, Saijo T, Yamamoto K, Imamura Y, Miyazaki T, Kakeya H, Ando T, Ogawa K, Kishi K, Tokimatsu I, Hayashi Y, Fujiuchi S, Yanagihara K, Miyazaki Y, Ichihara K, Mukae H, Kohno S, Izumikawa K. Clin Infect Dis; 2020 Feb 14; 70(5):835-842. PubMed ID: 30959519 [Abstract] [Full Text] [Related]
13. The clinical efficacy and safety of micafungin-itraconazole combination therapy in patients with pulmonary aspergilloma. Fujita M, Tao Y, Kajiki A, Ouchi H, Harada E, Ikegame S, Matsumoto T, Uchino J, Watanabe K, Nakanishi Y. J Infect Chemother; 2012 Oct 14; 18(5):668-74. PubMed ID: 22350405 [Abstract] [Full Text] [Related]
16. Clinical significance of measuring the blood concentration of itraconazole oral solution in the field of hematology. Shimoeda S, Nakagawa S, Kobayashi H, Yamato S, Kawano K, Ohta S. Biol Pharm Bull; 2010 Oct 14; 33(11):1861-6. PubMed ID: 21048312 [Abstract] [Full Text] [Related]